US FDA approves two biosimilars for blockbuster eye drug Eylea biztoc.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from biztoc.com Daily Mail and Mail on Sunday newspapers.
Kodiak Sciences will abandon
further development of its lead drug to treat a type of eye
disease after it failed in two late-stage studies, the company
said on Monday, sending its shares tumbling more.
The wet form of age-related macular degeneration (AMD) is currently treated with eye drugs that are blockbuster sellers. Opthea Limited is developing a wet AMD drug that goes after different targets and the biotech struck a pair of financing deals that provide it with the cash for pivotal tests that could show how well its approach works.